Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Cascadian Therapeutics, Inc. | d206944dex991.htm |
8-K - FORM 8-K - Cascadian Therapeutics, Inc. | d206944d8k.htm |
Exhibit 3.1
ONCOTHYREON INC.
CERTIFICATE OF AMENDMENT
TO THE
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Oncothyreon Inc., a Delaware corporation (the Corporation), hereby certifies that:
1. The name of the corporation is Oncothyreon Inc., and the corporation was originally incorporated pursuant to the General Corporation Law of the State of Delaware (the DGCL) on September 7, 2007 under the name Biomira Corporation.
2. Section 1.1 of Article I of the Amended and Restated Certificate of Incorporation of the Corporation is hereby amended and restated in its entirety to read as follows:
1.1 The name of the corporation is Cascadian Therapeutics, Inc.
3. This Certificate of Amendment to the Amended and Restated Certificate of Incorporation has been adopted by the Corporations Board of Directors in accordance with Section 242 of the DGCL.
4. This Certificate of Amendment to the Amended and Restated Certificate of Incorporation shall be effective at 12:01 AM on June 9, 2016.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its duly authorized officer as of this 7th day of June, 2016.
ONCOTHYREON INC. | ||
By: | /s/ Julie M. Eastland | |
Julie M. Eastland | ||
Vice President, Corporate Development and Chief Financial Officer |